Hologic, Inc. (NASDAQ:HOLX) Receives $84.62 Consensus PT from Analysts

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has been given a consensus recommendation of "Hold" by the seventeen research firms that are currently covering the stock, MarketBeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $84.62.

A number of research analysts recently issued reports on the company. Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Finally, Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th.

Hedge Funds Weigh In On Hologic

Several institutional investors and hedge funds have recently made changes to their positions in the business. General Partner Inc. bought a new position in Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the period. Finally, Smithfield Trust Co lifted its position in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 1.0 %

NASDAQ:HOLX traded down $0.56 during trading hours on Friday, reaching $57.80. 617,406 shares of the stock were exchanged, compared to its average volume of 1,966,903. Hologic has a twelve month low of $55.89 and a twelve month high of $84.67. The business has a 50-day moving average of $60.78 and a two-hundred day moving average of $69.69. The company has a market capitalization of $12.97 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 2.14 and a beta of 0.82. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.